Invivyd
Manufacturing · Connecticut, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
209 Church St, New Haven, Connecticut, 0...Phone Number
(781) 819-0080Website
www.invivyd.comRevenue
$55.9 MillionStock Symbol
IVVDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on developing innovative antibody-based therapies to protect against evolving viral threats. It uses a proprietary discovery and engineering platform to create potent monoclonal antibodies for prevention and treatment of infectious diseases. The company emphasizes cutting-edge research, viral surveillance, and adaptive solutions to address emerging health challenges globally.Explore more
Invivyd Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invivyd your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Invivyd had a recent Job posting/layoffs
Invivyd, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Invivyd recently announced quarterly report
Funding: Get notified immidiatlly once Invivyd has new funding data
Check if Invivyd has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Invivyd
Product Launch: Get notified when Invivyd launches new products
Check out if Invivyd is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Invivyd
Compare insights from companies similar to Invivyd, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invivyd is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Invivyd is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Invivyd.
Invivyd financials insights
Gather financial insights about Invivyd, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$50M
Series B
$80M
2021
Series C
$336M
Share Placement
$309.4M
Invivyd Tech Stack
A closer look at the technologies used by Invivyd
Most Recent Scoops
Project
Invivyd has upsized the DECLARATION trial by approximately 500 subjects following a pre-specified blinded sample size re-estimation, creating an incremental cohort time-shifted into the summer period to capture additional COVID events.
Clinical Operations
Project
Invivyd has reported that PEMGARDA, its Emergency Use Authorization-approved COVID-19 monoclonal antibody for moderately to severely immunocompromised persons, has demonstrated durable, variant-stable protection and serves as proof of concept for the company's antibody platform. The product has generated revenues in the range of $50 million to $60 million, growing at approximately 20% or more.
Proof of Concept (POC), Pharmaceuticals
Project
Invivyd is conducting the DECLARATION Phase III pivotal trial evaluating VYD2311 across three arms placebo, single dose, and repeat monthly dosing with a primary endpoint of reduction in symptomatic PCR-positive COVID-19. Based on prior placebo-controlled randomized controlled trial experience with similar antibodies, the expected efficacy range is approximately 70% to 90% risk reduction relative to placebo.
Medical Research, Clinical Operations
Project
Invivyd has announced an upsizing of the DECLARATION trial, triggered in early April by an inbuilt algorithm designed to capture sufficient disease events given the cyclical nature of COVID-19 infection waves, with pivotal data readout targeted for late third quarter. At the time of the upsizing announcement, a meaningful number of efficacy events had already been accumulated.
Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Invivyd
Sign Up For FreeTo access detailed company insights
Invivyd, Inc. is a biopharmaceutical company focused on developing innovative antibody-based therapies to protect against evolving viral threats. It uses a proprietary discovery and engineering platform to create potent monoclonal antibodies for prevention and treatment of infectious diseases. The company emphasizes cutting-edge research, viral sur... Read More
